NCT06271681View on ClinicalTrials.gov

Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2027

Study Completion Date

June 1, 2027

Conditions
Pneumococcal VaccinesImmunosuppression
Interventions
DRUG

21-valent pneumococcal conjugate vaccine

FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

VA Sierra Nevada Health Care System

FED